KLOW Get

Sources · the literature

The KLOW peptide reference list

Every cited study behind this site, component by component, with DOIs and PubMed links you can verify.

Back to the researchRead the safety spec

How to read this list

Every numbered citation across the site resolves here. The list is entirely component-level — studies of KPV, GHK-Cu, BPC-157 and TB-500 (or its parent protein thymosin beta-4) studied alone — plus the recent reviews and the regulatory references. There is no entry for a KLOW blend trial, because none has been published. Where a study used full-length thymosin beta-4 rather than the TB-500 fragment, that distinction is noted in the citation text so the two are never read as one.

  1. Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Med. 2026. (Used here for the blend-is-untested and regulatory-oversight statements.) ↗
  2. Staresinic M, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res. 2003;21:976-983. ↗
  3. Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, Yan Y, Sitaraman S, Merlin D. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166-178. ↗
  4. Pickart L, Vasquez-Soltero JM, Margolina A. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. BioMed Research International. 2015;2015:648108. ↗
  5. Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. International Journal of Molecular Sciences. 2018;19(7):1987. ↗
  6. Malinda KM, et al. Thymosin beta4 accelerates wound healing. J Invest Dermatol. 1999. (Full-length thymosin beta-4, not the TB-500 fragment.) ↗
  7. Wang Y, et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs. Front Pharmacol. 2022;13:1026182. ↗
  8. Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Med. 2026. (Lists TB-500/thymosin beta-4 and BPC-157; used here for FDA non-approval, WADA status and regulatory-oversight context.) ↗
  9. Ruff D, et al. A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers. Ann N Y Acad Sci. 2010. (Establishes TB-500's parent protein, thymosin beta-4, as the named peptide hormone/growth factor on the WADA Prohibited List S2 category.) ↗
  10. Hsieh MJ, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017;95:323-333. ↗
  11. Hostynek JJ, Dreher F, Maibach HI. Human skin penetration of a copper tripeptide in vitro as a function of skin layer. Inflammation Research. 2011;60(1):79-86. ↗
  12. Getting SJ, Christian HC, Lam CW, et al. Dissection of the anti-inflammatory effect of the core and C-terminal (KPV) alpha-melanocyte-stimulating hormone peptides. J Pharmacol Exp Ther. 2003;306(2):631-637. ↗
  13. Lee E, Burgess K. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Altern Ther Health Med. 2025;31(5):20-24. ↗
  14. Ruff D, et al. A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers. Ann N Y Acad Sci. 2010. (Phase 1; full-length thymosin beta-4, not the TB-500 fragment.) ↗
  15. Dymek M, Olechowska K, Hac-Wydro K, Sikora E. Liposomes as Carriers of GHK-Cu Tripeptide for Cosmetic Application. Pharmaceutics. 2023;15(10):2485. ↗
  16. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Altern Ther Health Med. 2021. (Retrospective case series, n=16.) ↗
  17. Morris DC, et al. A dose-response study of thymosin beta4 for the treatment of acute stroke. J Neurol Sci. 2014. (Full-length thymosin beta-4; non-monotonic dose response.) ↗
  18. Author group. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med. 2025. ↗